Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors

Cancers

Andrew J. Bellantoni¹  Lars M. Wagner¹ 

[1] Division of Pediatric Hematology/Oncology, Duke University, Durham, NC 27710, USA;

关键词: pediatric solid tumors;    targeted therapies;    precision medicine;    personalized medicine;    receptor tyrosine kinases;    tyrosine kinase inhibitors;   

DOI  :  10.3390/cancers13143531

来源: DOAJ

【 摘 要 】

Receptor tyrosine kinases are critical for the growth and proliferation of many different cancers and therefore represent a potential vulnerability that can be therapeutically exploited with small molecule inhibitors. Over forty small molecule inhibitors are currently approved for the treatment of adult solid tumors. Their use has been more limited in pediatric solid tumors, although an increasing number of single-agent and combination studies are now being performed. These agents have been quite successful in certain clinical contexts, such as the treatment of pediatric tumors driven by kinase fusions or activating mutations. By contrast, only modest activity has been observed when inhibitors are used as single agents for solid tumors that do not have genetically defined alterations in the target genes. The absence of predictive biomarkers has limited the wider applicability of these drugs and much work remains to define the appropriate patient population and clinical situation in which receptor tyrosine kinase inhibitors are most beneficial. In this manuscript, we discuss these issues by highlighting past trials and identifying future strategies that may help add precision to the use of these agents for pediatric extracranial solid tumors.

【 授权许可】

Unknown